Preclinical studies indicate that inhibition of transforming growth factor-beta (TGF-β) may inhibit tumor cell invasion and metastasis, reduce tumor neoangiogenesis, and enhance antitumor immunity [6–8]. Here, TGFB1 is linked to neoplasm.